Retatrutide is a synthetic peptide agonist that simultaneously targets three incretin and metabolic hormone receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). This tri-agonist profile distinguishes it from dual agonists like tirzepatide and represents a novel pharmacological approach to studying complex metabolic regulation.
Researchers have studied Retatrutide for its combined effects on insulin secretion, appetite regulation, and energy expenditure. The GLP-1R component has been associated with augmented insulin release and satiety signaling in preclinical studies, while the GIPR component is thought to complement these metabolic effects. The addition of glucagon receptor agonism distinguishes Retatrutide by potentially increasing energy expenditure and mobilizing hepatic glucose and lipid stores.
Preclinical and clinical research programs have generated substantial data on Retatrutide’s effects on body weight, cardiometabolic markers, and hepatic fat content. Animal model studies have examined its dose-dependent effects on food intake, body composition, and glycemic parameters. Its tri-agonist mechanism makes it a valuable research tool for studying the coordinated biology of the incretin and glucagon axes.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
